Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple‑negative breast cancer

Ayako Nakashoji, Akira Matsui, Aiko Nagayama, Yuko Iwata, Manami Sasahara, Yuya Murata

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The response of triple-negative breast cancer (TNBC) to chemotherapy is heterogeneous; particular subtype classifications based on mRNA gene expression analysis have been demonstrated to be associated with a pathological complete response (pCR). The aim of the present study was to investigate additional clinical and pathological characteristics associated with pCR status. The pathological and clinical characteristics of 40 TNBC patients who underwent neoadjuvant chemotherapy followed by surgery were retrospectively analyzed by dividing the cases into two groups according to the response to treatment: pCR (n=12) and non-pCR (n=28). Clinically, patients in the pCR group presented tumors with a significantly less advanced Tumor-Node-Metastasis stage (P=0.030) and mammographic calcification was less common (17 vs. 58%; P=0.034). Pathologically, whereas all cases in the pCR group (12/12,100%) were of the histological type ‘invasive ductal carcinoma, not otherwise specified' (IDC-NOS),the non-pCR group consisted of a lower proportion of IDC-NOS cases (20/28,71%) and more cases of special histological types, including mucinous, metaplastic, medullary and apocrine carcinomas (P=0.079). The positive rates of androgen receptor (AR) and forkhead-box A1 (FOXA1) tended to be lower in the pCR group (AR, 0 vs. 29%, P=0.079; FOXA1, 8 vs. 29%, P=0.233). The Ki-67 score was significantly higher in the pCR group than in the non-pCR group (P=0.041). The results suggest that patients with TNBC who present with clinically less advanced tumors and less frequent mammographic calcification are more likely to respond to chemotherapy. From a pathological standpoint, IDC-NOS type, negative AR status and higher Ki‑67 scores may be associated with chemotherapy sensitivity.

Original languageEnglish
Pages (from-to)4135-4141
Number of pages7
JournalOncology Letters
Volume14
Issue number4
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Ductal Carcinoma
Androgen Receptors
Breast Neoplasms
Drug Therapy
Neoplasms
Medullary Carcinoma
Neoplasm Metastasis
Gene Expression
Messenger RNA
Therapeutics

Keywords

  • Androgen receptor
  • Mammographic calcifications
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Triple‑negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple‑negative breast cancer. / Nakashoji, Ayako; Matsui, Akira; Nagayama, Aiko; Iwata, Yuko; Sasahara, Manami; Murata, Yuya.

In: Oncology Letters, Vol. 14, No. 4, 01.01.2017, p. 4135-4141.

Research output: Contribution to journalArticle

Nakashoji, Ayako ; Matsui, Akira ; Nagayama, Aiko ; Iwata, Yuko ; Sasahara, Manami ; Murata, Yuya. / Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple‑negative breast cancer. In: Oncology Letters. 2017 ; Vol. 14, No. 4. pp. 4135-4141.
@article{45bc6c466cca40818c63099bb80f7440,
title = "Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple‑negative breast cancer",
abstract = "The response of triple-negative breast cancer (TNBC) to chemotherapy is heterogeneous; particular subtype classifications based on mRNA gene expression analysis have been demonstrated to be associated with a pathological complete response (pCR). The aim of the present study was to investigate additional clinical and pathological characteristics associated with pCR status. The pathological and clinical characteristics of 40 TNBC patients who underwent neoadjuvant chemotherapy followed by surgery were retrospectively analyzed by dividing the cases into two groups according to the response to treatment: pCR (n=12) and non-pCR (n=28). Clinically, patients in the pCR group presented tumors with a significantly less advanced Tumor-Node-Metastasis stage (P=0.030) and mammographic calcification was less common (17 vs. 58{\%}; P=0.034). Pathologically, whereas all cases in the pCR group (12/12,100{\%}) were of the histological type ‘invasive ductal carcinoma, not otherwise specified' (IDC-NOS),the non-pCR group consisted of a lower proportion of IDC-NOS cases (20/28,71{\%}) and more cases of special histological types, including mucinous, metaplastic, medullary and apocrine carcinomas (P=0.079). The positive rates of androgen receptor (AR) and forkhead-box A1 (FOXA1) tended to be lower in the pCR group (AR, 0 vs. 29{\%}, P=0.079; FOXA1, 8 vs. 29{\%}, P=0.233). The Ki-67 score was significantly higher in the pCR group than in the non-pCR group (P=0.041). The results suggest that patients with TNBC who present with clinically less advanced tumors and less frequent mammographic calcification are more likely to respond to chemotherapy. From a pathological standpoint, IDC-NOS type, negative AR status and higher Ki‑67 scores may be associated with chemotherapy sensitivity.",
keywords = "Androgen receptor, Mammographic calcifications, Neoadjuvant chemotherapy, Pathological complete response, Triple‑negative breast cancer",
author = "Ayako Nakashoji and Akira Matsui and Aiko Nagayama and Yuko Iwata and Manami Sasahara and Yuya Murata",
year = "2017",
month = "1",
day = "1",
doi = "10.3892/ol.2017.6692",
language = "English",
volume = "14",
pages = "4135--4141",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple‑negative breast cancer

AU - Nakashoji, Ayako

AU - Matsui, Akira

AU - Nagayama, Aiko

AU - Iwata, Yuko

AU - Sasahara, Manami

AU - Murata, Yuya

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The response of triple-negative breast cancer (TNBC) to chemotherapy is heterogeneous; particular subtype classifications based on mRNA gene expression analysis have been demonstrated to be associated with a pathological complete response (pCR). The aim of the present study was to investigate additional clinical and pathological characteristics associated with pCR status. The pathological and clinical characteristics of 40 TNBC patients who underwent neoadjuvant chemotherapy followed by surgery were retrospectively analyzed by dividing the cases into two groups according to the response to treatment: pCR (n=12) and non-pCR (n=28). Clinically, patients in the pCR group presented tumors with a significantly less advanced Tumor-Node-Metastasis stage (P=0.030) and mammographic calcification was less common (17 vs. 58%; P=0.034). Pathologically, whereas all cases in the pCR group (12/12,100%) were of the histological type ‘invasive ductal carcinoma, not otherwise specified' (IDC-NOS),the non-pCR group consisted of a lower proportion of IDC-NOS cases (20/28,71%) and more cases of special histological types, including mucinous, metaplastic, medullary and apocrine carcinomas (P=0.079). The positive rates of androgen receptor (AR) and forkhead-box A1 (FOXA1) tended to be lower in the pCR group (AR, 0 vs. 29%, P=0.079; FOXA1, 8 vs. 29%, P=0.233). The Ki-67 score was significantly higher in the pCR group than in the non-pCR group (P=0.041). The results suggest that patients with TNBC who present with clinically less advanced tumors and less frequent mammographic calcification are more likely to respond to chemotherapy. From a pathological standpoint, IDC-NOS type, negative AR status and higher Ki‑67 scores may be associated with chemotherapy sensitivity.

AB - The response of triple-negative breast cancer (TNBC) to chemotherapy is heterogeneous; particular subtype classifications based on mRNA gene expression analysis have been demonstrated to be associated with a pathological complete response (pCR). The aim of the present study was to investigate additional clinical and pathological characteristics associated with pCR status. The pathological and clinical characteristics of 40 TNBC patients who underwent neoadjuvant chemotherapy followed by surgery were retrospectively analyzed by dividing the cases into two groups according to the response to treatment: pCR (n=12) and non-pCR (n=28). Clinically, patients in the pCR group presented tumors with a significantly less advanced Tumor-Node-Metastasis stage (P=0.030) and mammographic calcification was less common (17 vs. 58%; P=0.034). Pathologically, whereas all cases in the pCR group (12/12,100%) were of the histological type ‘invasive ductal carcinoma, not otherwise specified' (IDC-NOS),the non-pCR group consisted of a lower proportion of IDC-NOS cases (20/28,71%) and more cases of special histological types, including mucinous, metaplastic, medullary and apocrine carcinomas (P=0.079). The positive rates of androgen receptor (AR) and forkhead-box A1 (FOXA1) tended to be lower in the pCR group (AR, 0 vs. 29%, P=0.079; FOXA1, 8 vs. 29%, P=0.233). The Ki-67 score was significantly higher in the pCR group than in the non-pCR group (P=0.041). The results suggest that patients with TNBC who present with clinically less advanced tumors and less frequent mammographic calcification are more likely to respond to chemotherapy. From a pathological standpoint, IDC-NOS type, negative AR status and higher Ki‑67 scores may be associated with chemotherapy sensitivity.

KW - Androgen receptor

KW - Mammographic calcifications

KW - Neoadjuvant chemotherapy

KW - Pathological complete response

KW - Triple‑negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85028918251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028918251&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6692

DO - 10.3892/ol.2017.6692

M3 - Article

AN - SCOPUS:85028918251

VL - 14

SP - 4135

EP - 4141

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -